ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3102

Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy

Jon T. Giles1, S. Louis Bridges Jr.2, James R. O'Dell3, Stacey Cofield4, George Howard5, Jeffrey R. Curtis6 and Larry W. Moreland7, 1Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 5Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, 6University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 7Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adipokines, DMARDs, joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Higher levels of circulating adiponectin
have been linked to radiographic progression in RA in observational studies,
but never studied in the context of early RA with multiple treatment strategies.

Methods: We studied enrollees in the Treatment of Early
Aggressive RA (TEAR) Trial.  Participants had early, active RA, were seropositive,
or had ≥2 baseline erosions.  All received methotrexate and either etanercept
[immediately (IE) or as step-up therapy (SE)] or sulfasalazine +
hydroxychloroquine (i.e triple therapy) [immediately (IT) or as step-up therapy
(ST)].  Radiographs (baseline, and wks 48 and 102) were obtained and Sharp-van
der Heijde scores (SHS) calculated blind to sequence.  Available stored
baseline and 48wks serum samples from patients with complete radiographic data
were assayed for total adiponectin using a bead-based Luminex assay (R&D Systems). 
Assays were optimized, run in duplicate, and blocking for RF was used.  Multivariable
(MV) generalized linear modeling was used to model SHS change according to
baseline and change in adiponectin level, adjusting for relevant confounders.

Results: A total of 288 patients were studied.  Baseline
characteristics (mean age=51 yrs; 70% female; 74% non-Hispanic White; 91%
seropositive for RF or anti-CCP; median RA duration=1.2 months; mean
DAS28-ESR=5.8) were similar to those of the entire trial cohort.  Baseline
radiographic damage was observed in 86%, with a median SHS of 2.5 units. 
Median baseline adiponectin was 8.6 mg/L, and higher levels at week 48 were
observed in 46% of patients.  Factors significantly associated with increasing
adiponectin included female sex, lower baseline adiponectin, EULAR good
response at 48 weeks, and randomization to the IT group.  Radiographic
progression (≥2 unit increase in SHS) was observed in 10% at 48 wks.  MV
factors significantly associated included higher age, higher baseline ESR and
swollen joint count (SJC), longer RA duration, and increase in adiponectin.  Seropositivity,
baseline erosions, baseline adiponectin, BMI, and changes in DAS, ESR, or SJC
were not associated.  For adiponectin, each mg/L increase from baseline to
48wks was associated with a 10% higher odds of radiographic progression (OR=1.10;
p=0.009), an effect not altered with adjustment (Figure).  Interestingly, this
effect was observed only in patients without a 48wk EULAR good response
(Figure), and was seen regardless of randomized treatment allocation (Figure).  Similar
effects were observed for predicting radiographic progression at 102wks.

Conclusion: Rising adiponectin in the setting of
treatment non-response was a potent factor associated with radiographic
progression among RA patients at highest risk for joint damage in the early
phases of disease.  Additional mechanistic studies are needed to define the
physiologic basis for these findings.


Disclosure: J. T. Giles, None; S. L. Bridges Jr., None; J. R. O'Dell, None; S. Cofield, None; G. Howard, None; J. R. Curtis, Pfizer Inc, 2,Pfizer Inc, 5; L. W. Moreland, None.

To cite this abstract in AMA style:

Giles JT, Bridges SL Jr., O'Dell JR, Cofield S, Howard G, Curtis JR, Moreland LW. Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/increasing-circulating-adiponectin-after-dmard-initiation-is-associated-with-radiographic-progression-in-early-aggressive-ra-regardless-of-treatment-strategy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-circulating-adiponectin-after-dmard-initiation-is-associated-with-radiographic-progression-in-early-aggressive-ra-regardless-of-treatment-strategy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology